Targeting Neuropilin-1 with Nanobodies Reduces Colorectal Carcinoma Development.
cancer
immune checkpoint
immunotherapy
nanobody
neuropilin-1
plexin
semaphorin
single-domain antibody fragment
tumor-associated macrophage
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
30 Nov 2020
30 Nov 2020
Historique:
received:
22
10
2020
revised:
24
11
2020
accepted:
26
11
2020
entrez:
3
12
2020
pubmed:
4
12
2020
medline:
4
12
2020
Statut:
epublish
Résumé
Neuropilin-1 (NRP-1) is a co-receptor for semaphorins and vascular endothelial growth factor (VEGF) family members that can be expressed on cancer cells and tumor-infiltrating myeloid, endothelial and lymphoid cells. It has been linked to a tumor-promoting environment upon interaction with semaphorin 3A (Sema3A). Nanobodies (Nbs) targeting NRP-1 were generated for their potential to hamper the NRP-1/Sema3A interaction and their impact on colorectal carcinoma (CRC) development was evaluated in vivo through the generation of anti-NRP-1-producing CRC cells. We observed that tumor growth was significantly delayed and survival prolonged when the anti-NRP-1 Nbs were produced in vivo. We further analyzed the tumor microenvironment and observed that the pro-inflammatory MHC-II
Identifiants
pubmed: 33266104
pii: cancers12123582
doi: 10.3390/cancers12123582
pmc: PMC7760077
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : MIUR-PRIN
ID : 2017TATYMP
Organisme : Kom op tegen Kanker
ID : ANI146
Organisme : Fonds Wetenschappelijk Onderzoek
ID : S000218N
Organisme : Fonds Wetenschappelijk Onderzoek
ID : 1S24817N
Organisme : Vrije Universiteit Brussel
ID : SRP48
Références
Am J Pathol. 2010 Dec;177(6):3192-201
pubmed: 20971743
Anticancer Drugs. 2014 Jul;25(6):663-72
pubmed: 24583771
Nat Rev Immunol. 2005 Aug;5(8):641-54
pubmed: 16056256
Sci Rep. 2016 Apr 14;6:24249
pubmed: 27075020
J Control Release. 2019 Apr 10;299:107-120
pubmed: 30797866
Cancer Res. 2003 Sep 1;63(17):5230-3
pubmed: 14500350
Theranostics. 2019 Oct 15;9(25):7772-7791
pubmed: 31695800
Protein Sci. 2002 Mar;11(3):500-15
pubmed: 11847273
Behav Res Methods. 2007 May;39(2):175-91
pubmed: 17695343
Cancer Res. 2012 Jun 1;72(11):2705-13
pubmed: 22467173
Curr Opin Immunol. 2010 Apr;22(2):231-7
pubmed: 20144856
Nat Immunol. 2020 Sep;21(9):1010-1021
pubmed: 32661362
Cancer Cell. 2005 Sep;8(3):211-26
pubmed: 16169466
Clin Vaccine Immunol. 2012 May;19(5):823-4
pubmed: 22539564
Biochem J. 2008 Apr 15;411(2):211-26
pubmed: 18363553
Front Oncol. 2020 Jul 23;10:1182
pubmed: 32793488
Nat Commun. 2019 Jul 26;10(1):3345
pubmed: 31350404
Cancer Immunol Immunother. 2017 Sep;66(9):1131-1142
pubmed: 28432397
J Immunol. 2018 Aug 1;201(3):897-907
pubmed: 29898965
Leuk Lymphoma. 2008 Feb;49(2):331-8
pubmed: 18231921
J Clin Invest. 2007 May;117(5):1155-66
pubmed: 17476345
Nature. 2013 Sep 12;501(7466):252-6
pubmed: 23913274
J Immunol. 2006 Aug 1;177(3):1460-9
pubmed: 16849452
Z Gastroenterol. 2010 Jan;48(1):21-7
pubmed: 20072992
J Immunother Cancer. 2015 Dec 15;3:53
pubmed: 26673090
Front Immunol. 2017 Oct 10;8:1228
pubmed: 29067024
Blood. 2002 Dec 15;100(13):4622-8
pubmed: 12453880
Cancer Cell. 2013 Dec 9;24(6):687-9
pubmed: 24332035
J Gene Med. 2003 Aug;5(8):654-67
pubmed: 12898635
Proc Natl Acad Sci U S A. 2000 Mar 14;97(6):2573-8
pubmed: 10688880
Immunobiology. 2012 Dec;217(12):1266-72
pubmed: 22884356
Exp Ther Med. 2018 Aug;16(2):537-546
pubmed: 30116312
Cancer Res. 2010 Jul 15;70(14):5728-39
pubmed: 20570887
Cancer Res. 2014 Jan 1;74(1):24-30
pubmed: 24220244
Clin Vaccine Immunol. 2010 Jul;17(7):1086-93
pubmed: 20484568
Cancer Chemother Pharmacol. 2014 May;73(5):951-60
pubmed: 24633809
Vaccines (Basel). 2019 Aug 07;7(3):
pubmed: 31394834
Clin Cancer Res. 2007 Aug 15;13(16):4759-68
pubmed: 17699853
J Mol Biol. 2007 Feb 23;366(3):815-29
pubmed: 17196977
Cancer Cell. 2013 Dec 9;24(6):695-709
pubmed: 24332039
J Biomed Nanotechnol. 2013 Apr;9(4):551-8
pubmed: 23621013
Proc Natl Acad Sci U S A. 2001 Apr 10;98(8):4605-10
pubmed: 11274374
Cancer Res. 2012 Aug 15;72(16):4165-77
pubmed: 22719068
Immunity. 2008 Mar;28(3):402-13
pubmed: 18328743
Oncotarget. 2017 Oct 10;8(61):103682-103692
pubmed: 29262593
J Virol. 2010 Jun;84(11):5627-36
pubmed: 20237085
Eur J Immunol. 2004 Mar;34(3):623-630
pubmed: 14991591
Cancer Res. 2016 Jun 1;76(11):3166-78
pubmed: 27197153
Cancers (Basel). 2019 Jun 21;11(6):
pubmed: 31234464
J Clin Invest. 2018 Aug 31;128(9):3976-3990
pubmed: 29953416
Cancer Res. 2014 Mar 1;74(5):1287-93
pubmed: 24556724
Proc Natl Acad Sci U S A. 2009 Sep 22;106(38):16157-62
pubmed: 19805273
Oncotarget. 2017 Jun 27;8(26):41932-41946
pubmed: 28410210
Cell. 2017 Jun 1;169(6):1130-1141.e11
pubmed: 28552348
Invest New Drugs. 2014 Aug;32(4):653-60
pubmed: 24604265
J Exp Med. 2012 Oct 22;209(11):2001-16
pubmed: 23045606
Cancer Res. 2018 Feb 1;78(3):685-694
pubmed: 29097606